Dexcom CEO Kevin Sayer shared new data on the company’s first over-the-counter glucose sensor at the J.P. Morgan Healthcare Conference on Monday. Stelo, which is indicated for people who don’t ...

Continuous glucose monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose ...

Evaluate the expected performance of DexCom (DXCM) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics ...

Dexcom is working to move all of its sensors to its 15-day platform, like its Stelo product, and has made submissions to the FDA. Stelo’s features will also migrate to other systems, with the ...

Senseonics announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

Glucose monitoring without piercing the skin is a prize companies like Apple and Samsung have been aiming for. Now, Samsung ...

Dexcom (Nasdaq:DXCM) announced today that it plans to establish a direct presence in Italy, bringing its CGM technology to ...

Redburn Atlantic upgraded DexCom (DXCM) to Buy from Neutral with a price target of $115, up from $85. The company is positioned to benefit from ...

DexCom (NASDAQ:DXCM) shares popped 6% premarket ... This outlook considers sensor volume growth driven by increasing CGM access and awareness for people with diabetes, the continued rollout ...

Looking ahead, for the full-year 2025, Dexcom currently anticipates revenue of $4.60 billion, representing a growth of approximately 14 percent over 2024. This guidance considers sensor volume ...